- Home
- IFRX vs WLGS Comparison
IFRX vs WLGS Comparison
Compare IFRX & WLGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- WLGS
- Stock Information
- Founded
- IFRX 2007
- WLGS 1981
- Country
- IFRX Germany
- WLGS Hong Kong
- Employees
- IFRX N/A
- WLGS N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- WLGS Engineering & Construction
- Sector
- IFRX Health Care
- WLGS Consumer Discretionary
- Exchange
- IFRX Nasdaq
- WLGS Nasdaq
- Market Cap
- IFRX 117.8M
- WLGS 98.9M
- IPO Year
- IFRX 2017
- WLGS 2023
- Fundamental
- Price
- IFRX $1.00
- WLGS $0.24
- Analyst Decision
- IFRX Strong Buy
- WLGS
- Analyst Count
- IFRX 2
- WLGS 0
- Target Price
- IFRX $9.00
- WLGS N/A
- AVG Volume (30 Days)
- IFRX 322.6K
- WLGS 5.1M
- Earning Date
- IFRX 05-07-2025
- WLGS 04-15-2025
- Dividend Yield
- IFRX N/A
- WLGS N/A
- EPS Growth
- IFRX N/A
- WLGS N/A
- EPS
- IFRX N/A
- WLGS 0.02
- Revenue
- IFRX $171,642.00
- WLGS $7,272,879.00
- Revenue This Year
- IFRX $106.72
- WLGS N/A
- Revenue Next Year
- IFRX $66.89
- WLGS N/A
- P/E Ratio
- IFRX N/A
- WLGS $13.88
- Revenue Growth
- IFRX 162.79
- WLGS 66.93
- 52 Week Low
- IFRX $1.01
- WLGS $0.23
- 52 Week High
- IFRX $2.82
- WLGS $9.66
- Technical
- Relative Strength Index (RSI)
- IFRX 33.87
- WLGS 27.76
- Support Level
- IFRX $1.01
- WLGS $0.23
- Resistance Level
- IFRX $1.18
- WLGS $0.29
- Average True Range (ATR)
- IFRX 0.12
- WLGS 0.29
- MACD
- IFRX 0.01
- WLGS -0.18
- Stochastic Oscillator
- IFRX 3.66
- WLGS 0.45
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About WLGS Wang & Lee Group Inc.
WANG & LEE Group Inc operates as an investment holding company. The firm conducts its primary operations through its indirectly wholly owned subsidiary WANG and LEE CONTRACTING LIMITED (WLHK). WLHK provides contract engineering, installation, and out-fitting of the following products and services: low voltage (220v/phase 1 or 380v/phase 3) electrical systems, mechanical ventilation and air-conditioning systems (MVAC), fire safety systems, and water supply and sewage disposal systems.